Giuditta Illuzzi

机构：AstraZeneca (United Kingdom), Abzena (United Kingdom) · ORCID：0000-0003-1358-8424

发表论文 86 篇 · 总被引 1314 次 · h-index 19

代表论文

• Base editing screens define the genetic landscape of cancer drug resistance mechanisms (2024 · Nature Genetics · 被引 63)
• Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1 (2023 · Clinical Cancer Research · 被引 63)
• Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}- N -methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor (2024 · Journal of Medicinal Chemistry · 被引 32)
• Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair (2025 · NAR Cancer · 被引 6)
• Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in BRCA mutant cancer cells (2025 · Nucleic Acids Research · 被引 4)
• 350 (PB338): Structural variants of BRCA1/2 represent a novel biomarker of homologous recombination deficiency in multiple tumour types (2024 · European Journal of Cancer · 被引 1)